Swiss dermatology giant Galderma Group AG reported record financial results for 2024, with net sales reaching $4.41 billion, representing a 9.3% year-over-year growth at constant currency [1]. The company's performance demonstrates strong momentum across its three main business segments.

The company's Injectable Aesthetics division led revenue generation with $2.299 billion in sales, showing 9.6% growth. Dermatological Skincare contributed $1.331 billion with 10.7% growth, while Therapeutic Dermatology added $780 million, growing 6.1% [1,2].

"In 2024, Galderma continued to deliver strong performance while preparing the company for its next phase of growth," said Flemming Ørnskov, M.D., MPH, Chief Executive Officer of Galderma [1].

A significant milestone was the company's achievement of $1.031 billion in Core EBITDA, marking the first time it has exceeded the billion-dollar threshold. The company maintained a healthy profit margin of 23.4%, showing a 30-basis-point improvement over 2023 [2].

Looking ahead to 2025, Galderma projects net sales growth of 10-12% at constant currency, though it warns of a subdued first quarter due to market softness and impact from California wildfires [1]. The company also announced plans for a dividend payment of 0.15 CHF per share, subject to approval at the upcoming Annual General Meeting [3].

The company's international markets showed particularly strong performance, with 16.9% growth, while U.S. sales remained flat year-over-year. Notable developments included the successful launch of Nemluvio in the U.S. market, generating first-year sales of $23 million [1,2,3].